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Abstract: Increased attention to the prevalence of excessive sleepiness has led to a clear need to treat this symptom, thus 
reinforcing the need for a greater understanding of the neurobiology of sleep and wakefulness. Although the physiological 
mechanisms of sleep and wakefulness are highly interrelated, recent research reveals that there are distinct differences in 
the active brain processing and the specific neurochemical systems involved in the two states. In this review, we will ex-
amine the specific neuronal pathways, transmitters, and receptors composing the ascending arousal system that flow from 
the brainstem through the thalamus, hypothalamus, and basal forebrain to the cerebral cortex. We will also discuss the 
mutually inhibitory interaction between the core neuronal components of this arousal system and the sleep-active neurons 
in the ventrolateral preoptic nucleus, which serves as a brainstem-switch, regulating the stability of the sleep-wake states. 
In addition, we will review the role of homeostatic and circadian processes in the sleep-wake cycle, including the influ-
ence of the suprachiasmatic nucleus on coordination of sleep-wake systems. Finally, we will summarize how the above 
processes are reflected in disorders of sleep and wakefulness, including insomnia, narcolepsy, disorders associated with 
fragmented sleep, circadian rhythm sleep disorders, and primary neurological disorders such as Parkinson’s and Alz-
heimer’s diseases.  
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INTRODUCTION 
  Sleep loss and disorders of sleep/wake function are 
among the most common health problems reported in the 
United States. The estimated prevalence of syndromes of 
sleep-wake disorders in the US is about 50 to 70 million 
[75], and those who suffer from chronic sleep disorders have 
impaired daily functioning, compromised health status, and 
diminished quality of life [41]. As a consequence, during the 
past decade, much attention has been focused on the need to 
treat these conditions and thus on the neurophysiology of 
sleep and wakefulness. This research has led to a heightened 
understanding of the mechanisms regulating these behavioral 
states and the pathways, transmitters, and receptors involved 
in the sleep-wake cycle [14,17,34,50,53,59,68,98,99,107]. It 
is now apparent that the neural circuitry underlying the regu-
lation of sleep and wakefulness is discrete for each state yet 
interdependent; the very arousal systems that are inhibited by 
sleep-promoting neurons also serve to disrupt these same 
sleep processes to return the body to a wakeful state [99].  
  Alertness and associated forebrain and cortical arousal 
are mediated by several ascending pathways with distinct 
neuronal components that project from the upper brain stem 
near the junction of the pons and the midbrain [33]. One 
pathway innervates the thalamus, and the second extends 
into the posterior hypothalamus and forebrain. Key cell 
populations of the ascending arousal pathway include cho-
linergic, noradrenergic, serotoninergic, dopaminergic, and   
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histaminergic neurons located in the pedunculopontine and 
laterodorsal tegmental nucleus (PPT/LDT), locus coeruleus, 
dorsal and median raphe nucleus, and tuberomammillary 
nucleus (TMN), respectively. Projections from these various 
cell groups fire in a characteristic pattern to promote arousal. 
However, every 24 hours the arousal system is inhibited dur-
ing sleep by sleep-active -aminobutyric acid (GABA)-ergic 
and galaninergic neurons of the ventrolateral preoptic nu-
cleus (VLPO). The interaction between the VLPO and the 
branches of the ascending arousal pathway is mutually inhib-
iting, functioning much like an electrical “on-off” switch, 
enabling the body to maintain a stable state of wakefulness 
and sleep [34,59,98]. Normally, this “sleep-wake switch” 
design ensures stability between sleep and wakefulness while 
promoting rapid transitioning between the two behavioral 
states. Sleep disorders represent a pathology of this switch, 
which causes individuals to suffer from state instability, with 
wake intruding into sleep and/or sleep intruding into wake.  
  In this review, we will describe the arousal and sleep-
promoting neural pathways, looking closely at the brain cir-
cuitry, neurotransmitters, and chemical substrates involved 
in sleep control. In addition, we will examine the two proc-
esses engaged in the homeostatic and circadian regulation of 
sleep [1,12]. Finally, the review will describe how the 
aforementioned physiological and neurochemical processes 
are manifested in conditions such as insomnia, narcolepsy, 
disorders caused by fragmented sleep, circadian rhythm dis-
orders, and impaired sleep due to primary neurological dis-
ease, offering potential new targets for pharmaceutical 
treatment. If this research is successful, it could, over time, 
improve the considerable burden of disease associated with 
these debilitating sleep disorders.  368    Current Neuropharmacology, 2008, Vol. 6, No. 4 Schwartz and Roth 
THE ASCENDING AROUSAL SYSTEM INDUCES 
WAKEFULNESS 
  Contemporary models of the wake-sleep regulatory sys-
tem are based on the seminal research conducted by von 
Economo, Moruzzi, and Magoun. (A detailed review appears 
in Saper 2005 [99].) In 1930, von Economo reported that a 
viral illness known as encephalitis lethargica was caused by 
lesions of the posterior hypothalamus and rostral midbrain 
[122]. Consequently, he hypothesized that wakefulness is 
mediated by an ascending arousal system beginning in the 
brainstem, which remains active following midbrain inter-
ruption of the classical sensory pathways.  
  Nearly two decades later, Moruzzi, Magoun, and col-
leagues confirmed that waking behavior is indeed maintained 
by an “ascending reticular activating system,” originating in 
the upper brainstem adjacent to the junction of the pons and 
midbrain and continuing on to the diencephalon, where it 
separates into two branches [72,109]. In fact, it is now 
known that the ascending arousal system contains two major 
branches, each comprising discrete cell populations and neu-
rotransmitters [98] (Fig. 1). The first branch innervates the 
thalamus, activating relay neurons and reticular nuclei essen-
tial for thalamocortical transmission. Two cholinergic struc-
tures in the brainstem and basal forebrain serve as the origin 
of these projections to the principal thalamic nuclei – the 
PPT/LDT nuclei [40]. PPT/LDT neurons are most active 
during wakefulness and rapid eye movement (REM) sleep 
and discharge more slowly during non-REM (NREM) sleep, 
a period when cortical activity is reduced [99]. Transmission 
to the reticular nucleus of the thalamus is of particular im-
portance, as the site functions as a gating mechanism that can 
block the generation of thalamocortical rhythms and promote 
a state of excitability and wakefulness [57]. Other projec-
tions from the upper brainstem to the midline and intralami-
nar thalamic nuclei, which include the reticular formation, 
the parabrachial nucleus, and the monoaminergic systems 
(discussed below), are also believed to be involved in corti-
cal arousal [48].  
  The second branch of the ascending arousal system pro-
jects into the lateral hypothalamus, basal forebrain, and the 
cerebral cortex [45,96,98]. It comprises a number of mono-
aminergic cell populations, including noradrenergic neurons 
of the locus coeruleus, serotoninergic dorsal and median 
raphe nuclei, dopaminergic neurons of the ventral periaque-
ductal grey matter, and the histaminergic TMN. Several ad-
ditional cerebrocortical afferents have been identified: lateral 
hypothalamic peptidergic neurons, which contain melanin-
concentrating hormone or orexin/hypocretin, and basal fore-
brain nuclei, which contain acetylcholine or GABA [99]. 
Neurons in these monoaminergic systems have broad action 
potentials, discharging most rapidly during wakefulness, 
slowing during NREM sleep, and showing little activity dur-
ing REM sleep [8,33,110]. A similar pattern was reported in 
orexin/hypocretin neurons of the lateral hypothalamus [32, 
63]. In contrast, melatonin-concentrating neurons, which 
play an important role in REM homeostasis, are strongly 
active during REM sleep [119], and cholinergic neurons of 
the basal forebrain discharge at maximal rates during both 
REM sleep and active waking [49]. Lesions along this sec-
ond branch are associated with narcolepsy and other sleep 
disturbances in rats [37], with the loss of hypocretin cells, in 
particular, contributing to the difficulty in maintaining arou-
sal and the loss of muscle tone during cataplectic attacks 
[63].  
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  In sum, cholinergic neurons, monoaminergic cell popula-
tions, and orexin/hypocretin nuclei of the lateral hypothala-
mus located along the two branches of the ascending arousal 
system, discharge in a stereotypical and coordinated manner 
to promote cortical arousal, with each making unique, 
though overlapping and redundant, contributions to achieve 
and sustain wakefulness. During sleep, these circuits are 
blocked by neurons of the VLPO.  
THE VLPO AND THE SLEEP STATE 
  Following experiments by McGinty and colleagues, 
which demonstrated that lesions in the basal forebrain sup-
pressed sleep in cats [58], Sherin et al. determined that a 
group of ventrolateral preoptic neurons is specifically acti-
vated during sleep [107]. Neurons of the VLPO form a dense 
cluster and also extend more diffusely to innervate the 
monoaminergic systems in the hypothalamus and brainstem 
that participate in the modulation of cortical arousal (Fig. 2). 
VLPO efferents contain the inhibitory neurotransmitters 
GABA and galanin, and have been shown to play a central 
role in the mammalian brain in quieting the ascending mono-
aminergic arousal system during sleep [36,106].  
  Experiments in different animal species have indicated 
thatinjurytotheVLPO cluster and extended VLPO decreases 
NREM and REM sleep, respectively [51,53]. Neurons of the 
extended VLPO connect with pontine sites implicated in 
REM sleep gating – the LDT, dorsal raphe nucleus, and lo-
cus coeruleus [51], whereas the VLPO cluster provides out-
puttohistaminergicneuronsofthe TMN, which, as noted pre-
viously,areactiveduringwaking,reduce firing during NREM 
sleep, and cease discharge during REM sleep [42, 50]. 
  Afferents from the components of the monoaminergic 
arousal system also connect with the VLPO [18]. Noradrena-
line and serotonin released by axons from the locus coer-
uleus and median raphe nuclei, respectively, inhibit VLPO 
neurons in recordings of cells in hypothalamic slices [34], as 
do GABA [16] and galanin [46] produced by TMN neurons. 
(VLPO neurons do not appear to have receptors for hista-
mine.) Thus, the reciprocal inhibitory interaction of sleep-
promoting VLPO neurons and the noradrenergic, seroto-
ninergic, and cholinergic waking systems to which they pro-
ject establishes a remarkable dynamic, in which the VLPO is 
down-regulated by the very arousal systems it blocks during 
sleep [34,10]. 
THE BRAINSTEM CONTROL OF STATE STABIL-
ITY 
  The reciprocal inhibitory exchange between the major 
ascending monoaminergic arousal groups and the sleep-
inducing VLPO acts as a feedback loop; when monoamine 
nuclei discharge intensively during wakefulness, they inhibit 
the VLPO, and when VLPO fire rapidly during sleep, block 
the discharge of the monoamine cell groups [98]. This rela-
tionship is described as a bistable, “flip-flop” circuit, in 
which the two halves of the circuit strongly inhibit each 
other to produce two stable discharge patterns – on or off 
(Fig. 3). Intermediate states that might be partially “on and 
off” are resisted. This model helps clarify why sleep-wake 
transitions are relatively abrupt and mammals spend only 
about 1% to 2% of the day in a transitional state [99]. Hence, 
changes between sleep and arousal occur infrequently and 
rapidly. As will be described below, the neural circuitry 
Fig. (2). A schematic drawing showing primary projections of the VLPO to the main components of the ascending arousal system. Adapted 
from Saper 2005, pg 1258 [99]. 370    Current Neuropharmacology, 2008, Vol. 6, No. 4 Schwartz and Roth 
forming the sleep switch contrasts with homeostatic and cir-
cadian inputs, which are continuously and slowly modified 
[98]. 
Fig. (3). A schematic diagram of the flip-flop switch model. 
Adapted from Saper 2005, pg 1259 [99].
  Despite the bistability of the on/off feedback loop, if ei-
ther side is weakened or injured, unwanted instability can 
occur during both sleep and wake states, irrespective of 
which side is damaged. For instance, animals with VLPO 
lesions experience a 50% to 60% reduction in NREM and 
REM sleep time and wake up frequently during their sleep 
cycle [52]. Rapid sleep-wake cycling also is common in the 
elderly [6], who have fewer VLPO neurons [36]. These find-
ings suggest that when the self-reinforcing properties of the 
circuitry are weakened, individuals shift back and forth be-
tween sleep and wakefulness more frequently as well. 
PROMOTING SLEEP-STATE STABILITY 
  Orexin (hypocretin) is a neuropeptide produced by the 
neuronal cluster in the posterior portion of the lateral hypo-
thalamus [24,94]. Neurons containing orexin innervate the 
major nuclei implicated in sleep regulation. Specifically, 
orexin-1 receptors are found in the locus coeruleus, orexin-2 
receptors in the TMN, and both types in the median raphe 
nuclei and mesopontine reticular formation [54]. In contrast, 
orexin/hypocretin neurons only modestly affect the VLPO 
[18,95,128]. Therefore, it is possible that orexin/hypocretin 
may promote wakefulness by up-regulating monoaminergic 
neuronal populations.  
  This hypothesis has been confirmed in animals and hu-
mans. Experiments using orexin-receptor knockout mice 
produce behavioral symptoms and electroencephalographic 
results strikingly similar to those of humans with narcolepsy, 
which is characterized by sleep/wake as well as REM sleep 
dysregulation [17]. Similarly, humans who have narcolepsy 
with cataplexy have been shown to have few orexin neurons 
in the lateral hypothalamus and low orexin levels in the cere-
cerebrospinal fluid [61,86,113]. Fos expression in orexin/ 
hypocretin neurons was correlated positively with wakeful-
ness and negatively with NREM and REM sleep [32], 
whether measured during periods of sleep deprivation or 
following the use of stimulants such as modafinil [17,101]. 
Thus, excitatory orexin input may help regulate normal cor-
tical arousal and wakefulness.  
  Nevertheless, orexin/hypocretin-deficient mammals do 
not exhibit excess sleep. Instead, their on-off circuitry ap-
pears unstable, which leads to poor sleep-wake maintenance 
and dysfunctional switching [98]. Mochizuki et al. con-
firmed that the state instability during wakefulness experi-
enced by orexin-deficient mice is not a result of abnormal 
sleep homeostasis, poor circadian control, or defective 
monoaminergic systems but rather is the consequence of 
behavioral state instability due to low between-state transi-
tional thresholds [68]. In short, the asymmetric relationship 
between orexin/hypocretin neurons and arousal and sleep-
promoting cell populations may provide stability to the 
sleep-wake system by anchoring the flip-flop switch [99]. 
HOMEOSTATIC REGULATION OF SLEEP 
  Sleep is understood to be restorative, but precisely what 
is being restored is uncertain. As a homeostatic process, 
sleep allows the body to return to equilibrium when it is dis-
turbed. For instance, sleep deprivation tends to be followed 
by extra compensatory sleep to make up for the loss, albeit 
not on a minute-for-minute basis. Borbely and colleagues 
proposed a two-process model of sleep regulation to explain 
the homeostatic and circadian drives for sleep [1,12]. The 
homeostatic component, named Process S (sleep), is believed 
to derive from a substrate or protein that registers a homeo-
static “need to sleep” during periods of extended wakeful-
ness that is subsequently relieved during sleep. As NREM 
sleep appears to take precedence over REM sleep following 
acute sleep loss, it is probable that the homeostatic mecha-
nisms for the two sleep states differ [99]. 
  The underlying mechanisms remain unclear. However, 
McCarley and colleagues have shown that adenosine acting 
in the basal forebrain is a key mediator of homeostatic con-
trol (for a more detailed review, see McCarley 2007 [56]). 
Increased adenosine release accompanies the accumulation 
of the need to sleep, suggesting that the nucleoside, adeno-
sine, may be involved in the homeostatic control of sleep 
expression [9]. During periods of wakefulness, glycogen, the 
body’s principal store of energy, is exhausted [47]. As gly-
cogen is broken down into adenosine, extracellular levels of 
adenosine begin to accumulate in the basal forebrain [87], 
leading to the replenishment of glycogen levels with recov-
ered sleep [47,105]. Experimental models showed that the 
injection of adenosine or an adenosine A1 receptor agonist 
into the rat basal forebrain or the cat VLPO, respectively, 
promoted sleep by inhibiting multiple wake-promoting re-
gions of the brain or exciting sleep-promoting cell groups 
[101,112]. Adenosine also may excite VLPO neurons by 
disinhibiting GABAergic inputs [16]. Therefore, by inhibi-
ting the basal forebrain arousal system and triggering the 
VLPO nucleus, adenosine may act as homeostatic regulator 
of the sleep need. Recent evidence has shown that the sleep-
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its action at the A1 receptor, which triggers an intracellular 
cascade leading to increased adenosine A1 receptor produc-
tion [56]. Other mediators of homeostatic drive may be iden-
tified in the future.  
CIRCADIAN SLEEP REGULATION 
  A second component of the sleep-wake regulatory 
mechanism, which Borbely called Process C, involves cir-
cadian influences [1,12]. Dijk and Czeisler confirmed the 
role of the circadian pacemaker in the timing of the sleep-
wake cycle and regulation of the internal structure of sleep in 
a study in which 8 men lived in an environment free of time 
cues [27]. They found that sleep propensity and sleep struc-
turederive from the interactions of circadian and sleep-wake-
dependent oscillatory processes. The locus of this endoge-
nous circadian pacemaker is the suprachiasmatic nucleus 
(SCN) of the hypothalamus. 
  The SCN, which directs the circadian program, has been 
called the brain’s “master clock” [89]. Circadian timing, in 
which neurons fire in a 24-hour cycle, is organized in a hier-
archy of tissue-specific structures located throughout the 
body. These tissue-specific rhythms are coordinated by the 
SCN based on light input from the outside world during day-
time and by melatonin secretion during the dark cycle [15]. 
Damage to the SCN eliminates the circadian rhythms of 
many behaviors, including sleep [69]. In particular, lesions 
of the retinohypothalamic tract (RHT) of the SCN, which 
processes light input, cause animals to exhibit free-running 
behaviors, demonstrating that the SCN is necessary for syn-
chronization of circadian rhythms to the solar day [44]. 
  Early studies of circadian rhythms in rats with lesions of 
the SCN suggested that the homeostatic process was inde-
pendent of the circadian clock, as disrupted circadian sleep-
wake cycles following SCN destruction were not accompa-
nied by changes in overall sleep duration or recovery after 
sleep [64,65]. In 1993, however, Edgar and colleagues found 
that lesions of the primate SCN caused both a loss of cir-
cadian timing and increased total sleep time, suggesting an 
interaction of circadian and homeostatic processes. Accord-
ing to Edgar’s “opponent process” model, the SCN master 
circadian clock produces an alerting signal to enhance wake-
fulness and to actively counteract the accumulation of ho-
meostatic drive for sleep [30]. 
  A number of recent experimental studies have clarified 
the relationship between the SCN and the sleep-wake cycle. 
Most outputs from the SCN are directed at the subparaven-
tricular zone (SPZ) and dorsomedial nucleus of the hypo-
thalamus (DMH); in contrast, there is little innervation of the 
VLPO or orexin neurons [95,128]. Lu and colleagues 
showed that, in rats, lesions of the ventral SPZ disrupted 
measures of the circadian index of sleep by 90% but had 
little effect on body temperature; whereas, dorsal SPZ le-
sions lowered the circadian rhythms of temperature by 75% 
but did not affect sleep (<5%) [53]. This finding indicates 
that the SPZ is a complex region comprising neuronal sub-
populations that differentially regulate circadian rhythms of 
different physiological responses.  
  Moreover, the SPZ appears to link circadian input from 
the SCN to the DMH and preoptic targets, thereby amplify-
ing the circadian responses [53]. The DMH is a particularly 
important conduit for delivering signals from the SCN to the 
sleep-regulatory system. Lesions of the DMH reduced cir-
cadian rhythms of wakefulness, feeding, locomotor activity, 
and serum corticosteroid levels by 78% to 89% [19]. The 
DMH also sends GABAergic projections to the sleep-promo-
ting VLPO nucleus and glutamate-thyrotropin-releasing hor-
mone afferents to the excitatory lateral hypothalamic area 
[19]. Therefore, by integrating clock information from the 
SCN and the SPZ, the DMH plays a major role in regulating 
circadian sleep behavior. 
  In sum, an intricate multistage pathway connecting the 
SCN, the ascending arousal system, and the VLPO via the 
SPZ and DMH regulates circadian rhythms of sleep and 
other behaviors (Fig. 4). One rationale for this complexity is 
that it gives mammals the flexibility to adapt their behavioral 
and physiological cycles to environmental cues, and there-
fore establish patterns of rest-activity and sleep-wakefulness 
that are best able to meet the organism’s needs [97,99]. For 
instance, hypothalamic orexin neurons monitor indices of 
energy balance and mediate adaptive arousal due to food 
scarcity [127]. Whereas orexin expression in normal mice 
decreases as levels of blood glucose and leptin rise following 
food intake, mice with ablated orexin neurons do not respond 
to fasting with increased arousal and food-seeking activity. 
Precisely how external forces such as food availability and 
predation are able to reset homeostatic and circadian systems 
is currently unknown.  
Fig. (4). Circadian regulation of sleep-wake cycles. Adapted from 
Fuller 2006, pg 488 [33].
THE NEUROPATHOLOGY OF SLEEP-WAKE DIS-
ORDERS 
  At present, the pathophysiology of many sleep-wake dis-
orders is poorly understood [41]. Generally, a combination 
of biological, psychological, and social factors is implicated 
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review will describe the substrates and mechanisms that have 
been identified in the most common sleep-wake disorders 
and the clinical implications for the selection of suitable 
treatment strategies. 
Insomnia 
  Insomnia, the most frequently reported sleep disorder, is 
characterized as a state of hyperarousal in which stress is 
believed to activate the hypothalamic-pituitary-adrenal axis 
[41,85]. Vgontzas et al. demonstrated that, compared with 
healthy subjects, those with chronic insomnia had increased 
secretion of corticotropin and cortisol throughout the sleep-
wake cycle [121]. Additionally, Nofzinger and colleagues, 
using positron emission tomography (PET) studies to assess 
regional cerebral glucose metabolism, demonstrated that 
insomnia also is associated with greater whole-brain metabo-
lism during both sleep and wake periods and, notably, a fail-
ure of wake-promoting structures to deactivate during the 
transition from waking to sleep states [78]. Structures regu-
lating the sleep-wake cycle, such as the brainstem, hypo-
thalamus, and basal forebrain, are abnormally overactive 
during sleep. The ventral emotional neural system also is 
hyperactive during wakefulness in patients with primary 
insomnia and insomnia associated with depression, and this 
abnormal activity persists into NREM sleep [77]. These PET 
findings of whole brain hypermetabolism during sleep and 
wake states, and reduced waking metabolism in the prefron-
tal cortex of patients with insomnia, suggest that they have 
chronic insufficient sleep, which may explain daytime symp-
toms of fatigue [78]. The results also may explain why cog-
nitive factors (eg, worry) and environmental cues (eg, light 
exposure and unstable sleep schedules) perpetuate insomnia. 
A recent review by Roth and colleagues explores the patho-
physiology of insomnia and treatment implications in more 
detail [91]. For more information about treatment for insom-
nia, see Morin 2005 [71]. 
Narcolepsy 
  Narcolepsy is characterized by excessive daytime sleep-
ing and abnormal REM sleep [60,100]. Little is known about 
the cause of the disorder, and the little that is understood 
pertains to narcolepsy with cataplexy [23]. As noted above, 
individuals with this condition have marked neuronal loss 
(85% to 95%) in the hypothalamic regions responsible for 
producing orexin/hypocretin, including the dorsal and lateral 
hypothalamus, as well as in the locus coeruleus, thalamus, 
and the cerebral cortex [86,113]. The presence of gliosis in 
the orexin cell region suggests that narcolepsy is the conse-
quence of a neurodegenerative process [113]. Although the 
precise mechanisms are unknown, it is probable that both 
genetic and environmental triggers are involved in the onset 
of the condition [60]. 
Disorders Associated With Fragmented Sleep 
  Obstructive sleep apnea (OSA), the most prevalent type 
of sleep disordered breathing, is characterized by repeated 
episodes of partial (hypopneas) or complete collapse (ap-
neas) of the pharyngeal airway [41]. The apneic or hy-
popneic episodes lead to arousal and may induce hypoxemia 
and hypercapnia, as well as abnormally high levels of sym-
pathetic nervous system activity [74]; these neuropathologi-
cal changes are mediated by chemoreceptors in the carotid 
body and brainstem. High levels of sympathetic drive are 
evident even during periods of wakefulness, when subjects 
are breathing normally and there is no evidence of chemore-
ceptor activation [74]. OSA is associated with hypertension, 
cardiovascular disease, and depression [80,84]. OSA patients 
have a higher incidence of stroke and transient ischemic at-
tacks as well [76,80].  
  Another common disorder associated with fragmented 
sleep is restless legs syndrome (RLS). People with RLS re-
port a strong urge to move the legs, although the arms, trunk, 
or head and neck may be affected as well [4]. Symptoms of 
paresthesias worsen at night and at rest, and are relieved by 
movement, making it difficult to fall asleep or maintain sleep 
[41]. Altered dopamine and iron metabolism has been pro-
posed as a mechanism of RLS, and a strong familial compo-
nent has been identified as well [125]. Subjects with RLS 
have low iron levels in the substantia nigra and putamen (re-
gions of the brain that are responsible for controlling volun-
tary movement), and this disturbs the normal transmission of 
dopamine signals [3,116]. More specifically, Connor and 
colleagues suggested a defect in the regulation of transferrin 
receptors on neuromelanin-containing cells as a possible 
trigger [20]. The fact that RLS is common in individuals 
with iron deficiency provides clinical support for this hy-
pothesis [41]. In addition, dopaminergic agonists have been 
shown to be effective in the treatment of RLS, whereas do-
pamine antagonists aggravate sensorimotor symptoms and 
sleep disturbances [123,124,126]. Taken together, these find-
ings demonstrate that impaired iron metabolism is involved 
in the pathogenesis of RLS; whether other causative factors 
are involved is still to be determined [3]. 
Circadian Rhythm Sleep Disorders 
  Circadian rhythm sleep disorders stem from a chronic 
disturbance in the relationship between the circadian pace-
maker and environmental cues (eg, the light-dark cycle) [41]. 
In their 2005 ICSD update, the American Academy of Sleep 
Disorders identified 9 circadian disorders, including delayed 
sleep phase type, advanced sleep phase type, shift work type, 
nonentrained sleep-wake type, irregular sleep-wake type, and 
jet lag type [5]. The most prevalent of these conditions is 
shift work type circadian rhythm sleep disorder, also known 
as shift work disorder (SWD).  
  Shift work disorder is characterized by complaints of 
insomnia or excessive sleepiness (ES) during work hours 
scheduled during the customary sleep periods [5]; it is esti-
mated to affect about 32% of night-shift workers and 26% of 
rotating-shift workers [29]. It is believed to be caused by 
misalignment of circadian regulation and sleep-wake behav-
ior (ie, displaced work hours) [2]. Several different kinds of 
shift-work schedules may be implicated in the etiology of 
SWD – night shifts, early morning shifts, and rotating shifts, 
with the first two predominating. In people with SWD, total 
sleep time is reduced by 1 to 4 hours, and sleep quality is 
described as unsatisfactory. Patients may also complain of 
difficulties with sleep initiation and awakening; ES and di-
minished alertness, which may impair mental ability and 
work performance, also are hallmarks of SWD. The ES is 
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cadian alerting signal that corresponds to the altered work 
hours [5].  
  The pathology of SWD raises important safety concerns, 
particularly with respect to the elevated risk of motor vehicle 
accidents and workplace injury [79]. People with SWD also 
have higher rates of cardiovascular and gastrointestinal dis-
ease and depression, and are more likely to miss family and 
social activities than are shift workers without the disorder 
[29]. See Schwartz and Roth 2006 for a more complete re-
view of the burden of illness and management approaches to 
SWD [104].  
Disordered Sleep Associated with Primary Neurological 
Disorders: Alzheimer’s and Parkinson’s Diseases 
  Neurodegeneration in brain regions that are involved in 
sleep regulation can produce sleep-pattern abnormalities. 
Although the pathogenesis of sleep disturbances associated 
with Alzheimer’s disease (AD) is unknown [21,25], a rela-
tionship between disordered sleep and a number of behav-
ioral disturbances associated with dementia, such as aggres-
siveness and depression, has been identified [70,114]. Indi-
viduals with AD also have a higher prevalence of OSA [11], 
possibly because both conditions are associated with the 
APOE4 allele.  
  In contrast, the etiology of Parkinson’s disease (PD)-
related sleep disorders is better established. (Askenasy 2003 
provides a useful introduction [7].) PD is a dopaminergic 
disease, and patients with PD have fewer dopaminergic neu-
rons in cell groups of the ascending arousal system, relative 
to controls [129]. Other loci of arousal, such as noradrener-
gic and cholinergic nuclei, are depleted in PD as well [41]. 
There also is evidence that Lewy body degeneration in the 
lower brainstem, substantia nigra, and other mid- and fore-
brain gray matter regions begins relatively early in the dis-
ease process [13]. This finding is consistent with the obser-
vation that REM sleep disturbances are common in PD and 
may precede the onset of overt symptoms [13,41]. Despite 
these insights, much about the neurobiology of disordered 
sleep secondary to AD, PD, and other primary neurodegen-
erative conditions remains to be described.  
Treatment Considerations 
  Sleep disturbances are typically treated with a combina-
tion of behavioral and pharmacological therapies. The for-
mer include various psychological techniques such as cogni-
tive behavioral and sleep-restriction therapy, and strategies 
to improve sleep hygiene. Pharmacotherapeutic approaches 
include hypnotic agents to improve sleep onset and mainte-
nance, and wake-promoting agents such as sympathomimetic 
alerting agents (such as amphetamines and methylphenidate) 
and modafinil. Other therapies that have been beneficial in 
primary sleep-wake disorders include continuous positive 
airway pressure (CPAP) for OSA, antidepressants and so-
dium oxybate for narcolepsy with cataplexy, and benzodi-
azepine receptor agonists and melatonin selective receptor 
agonists for insomnia. Dopamine agonists, benzodiazepines, 
opioids, and anticonvulsants (including gabapentin) are pre-
scribed for RLS; all may be effective in treating various 
RLS-related symptoms. The dopamine agonists ropinirole 
and pramipexole have become first-line agents approved for 
the treatment of mild-to-moderate RLS. 
  Sleep problems secondary to neurological disease can be 
morecomplex.WhileADpatients with disturbed sleep should 
have the underlying symptoms addressed in the same manner 
as patients without dementia, treatment of PD-related sleep 
disturbances is complicated by the fact that dopaminergic 
medications used to treat the primary condition may cause 
nocturnal wakefulness, decreased short-wave sleep, and de-
creased sleep continuity at high doses [41]. Paradoxically, 
dopamine agonists may also cause ES [83], requiring the 
addition of a wake-promoting medication for symptomatic 
relief.  
Caffeine 
  Caffeine is often used as the initial treatment for ES 
caused by sleep deprivation. It achieves its wake-promoting 
effects by antagonizing adenosinergic neurons located in the 
hypothalamus and projecting into cells in the cortex, basal 
forebrain, and reticular activating system [67]. As described 
previously, endogenous adenosine levels rise as the need for 
sleep builds [9]. By inhibiting the basal forebrain arousal 
system and activating the VLPO, adenosine appears to be a 
fundamental component in the regulation of the homeostatic 
sleep system. Through its inhibition of A1 adenosine recep-
tors, caffeine prevents sleep onset and maintenance.  
  It is well established that caffeine affects alertness and 
cognitive performance, and may reduce the risk of accident 
and injury in sleep-deprived individuals. Caffeine supple-
ments in doses of 200 mg improved psychomotor perform-
ance tasks and vigilance in young, healthy, non-caffeine de-
pendent individuals [73]. However, tolerance can rapidly 
develop, and there is no long-term evidence validating its 
use. Caffeine is not indicated for use in narcolepsy, OSA, 
SWD, or idiopathic hypersomnia.  
Sympathomimetic Alerting Drugs 
  The mechanism of action of sympathomimetic alerting 
drugs (eg, dextro- and methamphetamine, methylphenidate) 
is direct or indirect stimulation of dopaminergic and noradre-
nergic nuclei, which in turn heightens the efficacy of the 
ventral periaqueductal grey area and locus coeruleus, both 
componentsof the secondary branch of the ascending arousal 
system. Amphetamines also activate non-wake-promoting 
CNS regions, such as the striatum and nucleus accumbens, 
causing the adverse effects (eg, nervousness, irritability, ano-
rexia, gastrointestinal problems, and rebound hypersomnia), 
seen with this class of wake-promoting drugs. In addition, 
amphetamines have a high abuse potential and can lead to 
dependence. Some patients may also develop tolerance to the 
alerting effects of these drugs, although the frequency varies 
across studies [81,82]. For these individuals, changing medi-
cations or introducing a drug “holiday” can improve the re-
sponse [10]. 
  Sympathomimetic drugs have long been used to treat 
narcolepsy, although many patients find that amphetamines 
do not provide a sufficient degree of daytime alertness [66]. 
For these patients, combining 2 or more alerting drugs (eg, 
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mines are available in a wide range of formulations and half-
lives to offer flexibility in dosing. The daily dose range for 
methylphenidate is up to 60 mg [90]; dextroamphetamine is 
up to 60 mg; and methamphetamine is 50 mg [38]. Am-
phetamines carry a relative contraindication for those with 
pre-existing cardiovascular problems, including hyperten-
sion. For all patients, regular blood pressure monitoring is 
recommended.  
Antidepressants and Sodium Oxybate as Anticataplectic 
Drugs 
  Cataplexy is usually treated with tricyclic antidepressants 
(TCAs), selective serotonin reuptake inhibitors (SSRIs) or 
norepinephrine reuptake inhibitors (NRIs) [41]. Newer anti-
depressants that are not TCAs or SSRIs, such as atomoxetine 
and venlafaxine, also may be effective [10]. In addition, pa-
tients may benefit from sodium oxybate. Although the 
mechanism of sodium oxybate has been studied extensively, 
it remains unknown [115]. The treatment is especially effec-
tive when combined with other alerting drugs and has been 
shown to reduce nocturnal sleep disruptions and help con-
solidate sleep [10]. 
Modafinil and Armodafinil 
  Modafinil is a unique wake-promoting compound that is 
pharmacologically and chemically distinct from other CNS 
stimulants. A substantial body of research has sought to elu-
cidate the precise mechanism of action of modafinil; to date, 
the question remains unresolved. (See Schwartz 2005 for a 
detailed review of the pharmacology of the drug [102].) Pre-
clinical studies show that modafinil has low affinity for re-
ceptors for noradrenaline, serotonin, GABA, adenosine, or 
histamine [26,62,108]. However, Scammell and colleagues 
reported that modafinil increased activity in the TMN and 
orexin nuclei, 2 regions involved in the promotion of wake-
fulness [101]. The drug also potentiates noradrenergic nuclei 
in the VLPO, thereby inhibiting sleep [35]. Consequently, it 
is believed that by down-regulating sleep-promoting neurons 
in the VLPO, modafinil enables components of the ascend-
ing arousal neuronal pathway (eg, the TMN) to remain active 
[102]. Further research will be necessary to confirm this hy-
pothesis. 
  Modafinil is approved for the treatment of ES associated 
with narcolepsy, OSA, and SWD. Multiple randomized 
clinical trials in these 3 conditions demonstrated that mo-
dafinil produced significant improvement, relative to pla-
cebo, in subjective and objective measures of ES, including 
the Epworth Sleepiness Scale, Multiple Sleep Latency Test, 
and Maintenance of Wakefulness Test [22,28, 117,118]. 
Overall clinical condition and sustained attention and reac-
tion time, as measured by the Clinical Global Impression of 
Change and Psychomotor Vigilance Test, respectively, also 
improved significantly. In addition, patients with SWD given 
modafinil reported a significantly lower rate of driving acci-
dents or near accidents while commuting [22]. The drug was 
well tolerated in these clinical trials, with mild-to-moderate, 
transient headache being the primary reported adverse event 
[22,28,117,118]. There also have been cases of transient in-
somnia. Overall, modafinil has a superior side effect profile 
compared with other wake-promoting drugs, and has a low 
potential for abuse. For these reasons, the agent has become 
a treatment of choice for narcolepsy, and is the only cur-
rently available medication that is approved for OSA patients 
treated with CPAP with ongoing daytime ES, as well as pa-
tients with SWD [102]. The standard dose is 200 to 400 mg 
daily [88], although some patients with severe sleepiness 
may require higher doses, and doses up to 600 mg in divided 
doses have shown a subjective and objective benefit over 
lower doses in narcolepsy patients (400 mg at 7 am, 200 mg 
at noon [103].  
  Armodafinil is the R-isomer of modafinil and is approved 
for treatment of ES associated with OSA, SWD, and narco-
lepsy. In clinical trials, armodafinil has been shown to im-
prove wakefulness throughout the day in patients with OSA 
or narcolepsy [41] and during the night shift and the com-
mute home in patients with SWD [30]. The most common 
adverse events reported in clinical studies of armodafinil 
were headache, nausea, and insomnia. 
Benzodiazepine Receptor and Melatonin Selective Recep-
tor Agonists  
  Treatment of insomnia typically involves a combination 
of behavioral and pharmacological approaches. Among the 
psychological techniques that have demonstrated effective-
ness are stimulus-control and sleep-restriction therapies, re-
laxation training, cognitive behavioral therapy, and sleep 
hygiene education [69]. The most frequently prescribed 
pharmacotherapies for insomnia are GABA type A (GABA-
A) modulators. These drugs target the benzodiazepine recep-
tors in the CNS. Benzodiazepine (eg, temazepam, triazolam) 
and non-benzodiazepine (zolpidem, eszopiclone) hypnotics 
may produce daytime sedation side effects in some patients, 
but these problems do not limit their utility. Benzodiazepine 
receptor agonists have an abuse and dependence potential 
(Schedule IV), especially in patients with a history of sub-
stance abuse. Careful surveillance of at-risk individuals is 
recommended. Benzodiazepine hypnotics also may cause 
next-day cognitive and motor impairments [111,120] and 
may engender withdrawal symptoms (eg, rebound insomnia, 
anxiety, irritability, gastrointestinal distress), particularly 
following long-term or high-dose use [39].  
  The recently approved MT1/MT2 melatonin receptor 
agonist ramelteon is a proposed alternative to the benzodi-
azepine receptor agonists for the treatment of insomnia char-
acterized by difficulty with sleep onset [93]. MT1 and MT2 
receptors are located in the SCN and contribute to mainte-
nance of the circadian sleep-wake cycle. As the drug has no 
affinity for benzodiazepine, dopamine, and opiate receptors, 
or for ion channels and receptor transporters, ramelteon has 
limited potential for abuse and cognitive and functional im-
pairment. A dose-ranging, double-blind, cross-over study 
comparing ramelteon, triazolam, and placebo found that, 
compared with placebo, ramelteon caused no significant ef-
fect on these problematic adverse events at up to 20 times the 
recommended dose (8 mg daily at bedtime) [43]. In contrast, 
triazolam negatively affected measures of motor and cogni-
tive performance. Ramelteon significantly reduced latency of 
persistent sleep and increased total sleep time in adults with 
chronic insomnia in 2 double-blind randomized, controlled 
trails [31,92]. There also were no apparent next-day cogni-Neurophysiology of Sleep and Wakefulness  Current Neuropharmacology, 2008, Vol. 6, No. 4    375
tive or motor effects or evidence of rebound insomnia or 
withdrawal effects following treatment discontinuation in 
these trials. Ramelteon should be considered for patients 
with sleep-onset insomnia, particularly those who are treat-
ment naïve, who have a history of substance abuse, who are 
older adults susceptible to the effects of benzodiazepine and 
non-benzodiazepine hypnotics, and who require minimal 
interference with the arousal response.  
CONCLUSION 
  Recent insight into the physiological patterns of sleep 
and wakefulness has shown that different brain-processing 
networks and neurochemical systems are involved in both 
states. The particular neuronal pathways, transmitters, and 
receptors that make up the ascending arousal system cen-
tered in the hypothalamus interact with sleep-active neurons 
in the VLPO in a flip-flop switch to produce distinct sleep-
wake states with abrupt transitions. Progress in understand-
ing the neural circuitry underlying the regulation of sleep-
wake states has led to the identification of new mechanisms 
and substrates, and studies are now underway to investigate 
these potential targets. In the future, the products of these 
investigations may offer novel approaches for the treatment 
of these common and intractable conditions. 
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